Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observational registry of pembrolizumab in neoadjuvant treatment for resectable advanced esophageal cancer
ChiCTR2100053631Phase 4Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of pembrolizumab in esophageal cancer and esophagogastric junction cancer (2 arms), sponsored by Xijing Hospital. Primary endpoints: Physical condition score and Adverse event. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
03
Conditions
esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on ChiCTR2100053631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053631.